Visx PRK laser
This article was originally published in The Gray Sheet
Executive Summary
Company submits two-year follow-up data to FDA for its Twenty/Twenty excimer laser for the treatment of myopia via photorefractive keratectomy. The firm submitted a premarket approval application for the device in June 1993. In addition, the firm says that FDA has asked the company for more information on its pending application for use of the Twenty/Twenty in phototherapeutic keratectomy. In response to a panel request, Visx submitted one-year follow up data on PTK patients in May
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.